Meeting
2022 ASCO Gastrointestinal Cancers Symposium
A randomized phase II trial of MEK and CDK4/6 inhibitors vesus tipiracil/trifluridine (TAS-102) in metastatic KRAS/NRAS mutant (mut) colorectal cancer (CRC).
Authors
Michael Sangmin Lee
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Michael Sangmin Lee , Tyler J. Zemla , Kristen Keon Ciombor , Autumn Jackson McRee , Mehmet Akce , Shaker R. Dakhil , Brandy L. Jaszewski , Fang-Shu Ou , Tanios S. Bekaii-Saab , Scott Kopetz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03981614
DOI
10.1200/JCO.2022.40.4_suppl.116
Abstract #
116
Poster Bd #
F4
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Preclinical drug testing for clinical trial planning of novel combinative therapy with PI3K and MAPK inhibitors in colorectal cancer(CRC).
First Author: Cha Len Lee
Poster
2016 ASCO Annual Meeting
A Phase I/Ib study of MEK162 (binimetinib), a MEK inhibitor, in combination with carboplatin and pemetrexed in patients with non-squamous NSCLC.
First Author: Safiya Karim
Poster
2015 Gastrointestinal Cancers Symposium
Phase II Pharmacodynamic Trial of Palbociclib in Patients with KRAS Mutant Colorectal Cancer.
First Author: Mark H. O'Hara
Poster
2024 ASCO Annual Meeting
Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC): Preliminary findings.
First Author: Benjamin Adam Weinberg